Get the Stockscreener App
9.16
0.11%
0.010
After Hours:
9.18
0.02
+0.22%
Bioventus Inc stock is traded at $9.16, with a volume of 341.17K.
It is up +0.11% in the last 24 hours and up +4.69% over the past month.
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
See More
Previous Close:
$9.15
Open:
$9.2
24h Volume:
341.17K
Relative Volume:
1.09
Market Cap:
$617.09M
Revenue:
$568.09M
Net Income/Loss:
$27.27M
P/E Ratio:
27.96
EPS:
0.3276
Net Cash Flow:
$71.41M
1W Performance:
+2.69%
1M Performance:
+4.69%
6M Performance:
+35.50%
1Y Performance:
-2.86%
1-Day Range:
$9.03
$9.29
1-Week Range:
$8.46
$9.295
52-Week Range:
$5.81
$9.56
Bioventus Inc Stock (BVS) Company Profile
Name
Bioventus Inc
Sector
Industry
Phone
(919) 474-6700
Address
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
9.16 | 616.42M | 568.09M | 27.27M | 71.41M | 0.3276 |
ABT
Abbott Laboratories
|
104.83 | 180.82B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.65 | 125.72B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.89 | 111.16B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
69.78 | 101.28B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.67 | 47.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Initiated | Barrington Research | Outperform |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-07-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-09-23 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-22-22 | Downgrade | Craig Hallum | Buy → Hold |
| Nov-09-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Mar-15-22 | Initiated | Craig Hallum | Buy |
| Nov-15-21 | Resumed | Morgan Stanley | Overweight |
| Nov-10-21 | Resumed | JP Morgan | Overweight |
| Jul-01-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-08-21 | Initiated | Canaccord Genuity | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | JP Morgan | Overweight |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
View All
Bioventus Inc Stock (BVS) Latest News
Bioventus (BVS) CFO vests 18,625 RSUs with 8,091 shares withheld for taxes - Stock Titan
(BVS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Bioventus Inc.(NasdaqGS: BVS) added to S&P Healthcare Equipment Select Industry Index - marketscreener.com
BVS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aug Wrap: Does Bioventus Inc offer margin of safetyEarnings Growth Summary & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Barrington Research initiates coverage of Bioventus (BVS) with outperform recommendation - MSN
Does Bioventus Inc have a competitive edge2026 Buyback Activity & Growth Focused Stock Pick Reports - baoquankhu1.vn
Bioventus (BVS) CFO receives major stock awards and exercises RSUs - Stock Titan
Bioventus (BVS) SVP granted RSUs, options and exercises prior awards - Stock Titan
Bioventus (BVS) SVP & General Counsel receives RSU, option grants and exercises awards - Stock Titan
Bioventus (BVS) CEO adds major RSU and option grants, exercises awards - Stock Titan
Travel Stocks: Is Bioventus Inc attractive for institutional investors2026 WrapUp & Community Shared Stock Ideas - baoquankhu1.vn
Bioventus : Corporate PresentationMarch 2026 - marketscreener.com
Divisadero Street Capital Management LP Sells 385,116 Shares of Bioventus Inc. $BVS - MarketBeat
Insider Sell: Michelle Mcmurry-heath Sells 12,000 Shares of Biov - GuruFocus
Bioventus (NASDAQ:BVS) Director Michelle Mcmurry-Heath Sells 12,000 Shares - MarketBeat
Bioventus (BVS) director logs open-market sale of 12,000 shares - Stock Titan
Bioventus Receives Consensus Buy Rating from Analysts - National Today
Bioventus Inc. (NASDAQ:BVS) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates - MSN
Bioventus stock delivers 63% return after Fair Value signal By Investing.com - Investing.com Australia
Bioventus stock delivers 63% return after Fair Value signal - Investing.com India
Liquidity Mapping Around (BVS) Price Events - Stock Traders Daily
Orthobiologics Market to Surpass USD 9 Billion by 2031 Amid Rising Osteoarthritis Cases and Advancements in Regenerative Therapies, Says Mordor Intelligence - GlobeNewswire Inc.
BVS (NASDAQ: BVS) files Form 144 for 12,000 Class A shares via Fidelity - Stock Titan
Earnings call transcript: Bioventus Inc. Q4 2025 beats EPS estimates, stock surges - Investing.com Nigeria
Bioventus Earnings Call Signals Profitable Growth Ahead - TipRanks
BVS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bioventus Inc. (NASDAQ:BVS) Q4 2025 earnings call transcript - MSN
Momentum Shift: How is Bioventus Inc managing supply chain issues2026 Breakouts & Breakdowns & Stepwise Trade Signal Implementation - baoquankhu1.vn
Risks Report: Is Bioventus Inc exposed to currency risksJuly 2025 Chart Watch & Growth Focused Stock Pick Reports - baoquankhu1.vn
Craig-Hallum Maintains Buy on Bioventus Inc (BVS) March 2026, PT $16 - Meyka
Aug Action: Will Bioventus Inc benefit from rising consumer demandProduct Launch & Technical Pattern Alert System - baoquankhu1.vn
Bioventus (NYSE:BVS) In Focus as NYSE Composite Tracks MedTech Moves - Kalkine Media
Bioventus (BVS) Receives Updated Price Target from Barrington Re - GuruFocus
Bioventus (NYSE:BVS) Stock Price Expected to Rise, Barrington Research Analyst Says - MarketBeat
Bioventus (NASDAQ:BVS) Shares Down 8.2%Here's Why - MarketBeat
Bioventus (NYSE:BVS) Given New $16.00 Price Target at Craig Hallum - MarketBeat
Craig-Hallum raises Bioventus stock price target on guidance beat By Investing.com - Investing.com India
Craig-Hallum raises Bioventus stock price target on guidance beat - Investing.com India
Barrington Adjusts Price Target on Bioventus to $14 From $13, Maintains Outperform Rating - marketscreener.com
Bioventus Inc. (NASDAQ:BVS) Q4 2025 Earnings Call Transcript - Insider Monkey
Bioventus: Q4 Earnings Snapshot - theheraldreview.com
Bioventus Q4 Earnings Assessment - Sahm
Bioventus earnings beat by $0.04, revenue topped estimates - Investing.com Australia
BVS Targets Revenue Range of $600M-$610M for FY26 - GuruFocus
Bioventus Q4 Earnings Call Highlights - MarketBeat
Bioventus Inc (BVS) Q4 2025 Earnings Call Highlights: Strong Org - GuruFocus
Bioventus (NYSE:BVS) Shares Gap UpHere's Why - MarketBeat
Bioventus Shares Rise After Analyst Upgrade - National Today
Bioventus Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Bioventus Inc Stock (BVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):